Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...